CA3220850A1 - Fluorinated tryptamine compounds, analogues thereof, and methods using same - Google Patents
Fluorinated tryptamine compounds, analogues thereof, and methods using same Download PDFInfo
- Publication number
- CA3220850A1 CA3220850A1 CA3220850A CA3220850A CA3220850A1 CA 3220850 A1 CA3220850 A1 CA 3220850A1 CA 3220850 A CA3220850 A CA 3220850A CA 3220850 A CA3220850 A CA 3220850A CA 3220850 A1 CA3220850 A1 CA 3220850A1
- Authority
- CA
- Canada
- Prior art keywords
- fluoro
- ethyl
- indo1
- amine
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163195943P | 2021-06-02 | 2021-06-02 | |
| US63/195,943 | 2021-06-02 | ||
| US202163288313P | 2021-12-10 | 2021-12-10 | |
| US63/288,313 | 2021-12-10 | ||
| PCT/US2022/032000 WO2022256554A1 (en) | 2021-06-02 | 2022-06-02 | Fluorinated tryptamine compounds, analogues thereof, and methods using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3220850A1 true CA3220850A1 (en) | 2022-12-08 |
Family
ID=84324579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3220850A Pending CA3220850A1 (en) | 2021-06-02 | 2022-06-02 | Fluorinated tryptamine compounds, analogues thereof, and methods using same |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240286998A1 (enExample) |
| EP (1) | EP4347559A4 (enExample) |
| JP (1) | JP2024523822A (enExample) |
| KR (1) | KR20240017363A (enExample) |
| AU (1) | AU2022287013A1 (enExample) |
| BR (1) | BR112023025340A2 (enExample) |
| CA (1) | CA3220850A1 (enExample) |
| CO (1) | CO2023018652A2 (enExample) |
| IL (1) | IL308944A (enExample) |
| MX (1) | MX2023014437A (enExample) |
| WO (1) | WO2022256554A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4396162A4 (en) | 2021-09-03 | 2025-11-12 | Alexander Shulgin Res Institute Inc | ASYMMETRIC ALLYL TRYPTAMINES |
| US20250091993A1 (en) * | 2022-01-27 | 2025-03-20 | Terran Biosciences Inc. | Salts and solid forms of n-ethyl-2-(5-fluoro-1h-indol-3-yl)-n-methylethan-1-amine |
| US12129234B1 (en) | 2023-08-03 | 2024-10-29 | Gilgamesh Pharmaceuticals, Inc. | Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine |
| US12180158B1 (en) | 2023-08-03 | 2024-12-31 | Gilgamesh Pharmaceuticals, Inc. | Crystalline fumarate salts of n-ethyl-2-(5-fluoro-1H-indol-3-yl)-n-methylethan-1-amine |
| WO2025052388A1 (en) * | 2023-09-07 | 2025-03-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Psychedelic compounds, methods of their preparation and uses thereof |
| WO2025104491A1 (en) * | 2023-11-14 | 2025-05-22 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2223239A1 (en) * | 1995-06-06 | 1996-12-12 | Schering Corporation | Substituted benzene-fused hetero- and carbocyclics as neurokinin antagonists |
| DE19615232A1 (de) * | 1996-04-18 | 1997-10-23 | Merck Patent Gmbh | Neue Carbamoylderivate und deren Verwendung als 5-HT ¶1¶¶A¶-Antagonisten |
| US6100291A (en) * | 1998-03-16 | 2000-08-08 | Allelix Biopharmaceuticals Inc. | Pyrrolidine-indole compounds having 5-HT6 affinity |
| AR021509A1 (es) * | 1998-12-08 | 2002-07-24 | Lundbeck & Co As H | Derivados de benzofurano, su preparacion y uso |
| US6800637B2 (en) * | 2002-09-12 | 2004-10-05 | Wyeth | Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines |
| CA3052974A1 (en) * | 2017-02-09 | 2018-08-16 | CaaMTech, LLC | Compositions and methods comprising a psilocybin derivative |
| EP3793360A4 (en) * | 2018-05-16 | 2022-02-16 | University of Florida Research Foundation | Methods and compositions for substituted 2,5-diketopiperazine analogs |
| GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| BR112022015379A2 (pt) * | 2020-02-04 | 2022-09-27 | Mindset Pharma Inc | Derivados de 3-pirrolidino-indol como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc |
| KR20260008838A (ko) * | 2020-02-18 | 2026-01-16 | 길가메쉬 파마슈티컬스, 인코포레이티드 | 기분 장애 치료에 사용되기 위한 특이적 트립타민 |
| AU2021337466A1 (en) * | 2020-09-01 | 2023-03-30 | Enveric Biosciences Canada Inc. | Halogenated psilocybin derivatives and methods of using |
| AU2021343525A1 (en) * | 2020-09-20 | 2023-05-18 | Tactogen Inc | Advantageous tryptamine compositions for mental disorders or enhancement |
| JP2023553094A (ja) * | 2020-12-07 | 2023-12-20 | マインドセット ファーマ インコーポレイテッド | 中枢神経系障害の治療のためのセロトニン作動性薬としての3位環-アミンインドール誘導体 |
-
2022
- 2022-06-02 US US18/565,565 patent/US20240286998A1/en active Pending
- 2022-06-02 CA CA3220850A patent/CA3220850A1/en active Pending
- 2022-06-02 AU AU2022287013A patent/AU2022287013A1/en active Pending
- 2022-06-02 BR BR112023025340A patent/BR112023025340A2/pt unknown
- 2022-06-02 IL IL308944A patent/IL308944A/en unknown
- 2022-06-02 EP EP22816868.8A patent/EP4347559A4/en active Pending
- 2022-06-02 KR KR1020237044652A patent/KR20240017363A/ko active Pending
- 2022-06-02 JP JP2023574858A patent/JP2024523822A/ja active Pending
- 2022-06-02 MX MX2023014437A patent/MX2023014437A/es unknown
- 2022-06-02 WO PCT/US2022/032000 patent/WO2022256554A1/en not_active Ceased
-
2023
- 2023-12-29 CO CONC2023/0018652A patent/CO2023018652A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4347559A4 (en) | 2025-04-09 |
| IL308944A (en) | 2024-01-01 |
| KR20240017363A (ko) | 2024-02-07 |
| BR112023025340A2 (pt) | 2024-02-20 |
| MX2023014437A (es) | 2024-03-08 |
| EP4347559A1 (en) | 2024-04-10 |
| JP2024523822A (ja) | 2024-07-02 |
| CO2023018652A2 (es) | 2024-01-25 |
| US20240286998A1 (en) | 2024-08-29 |
| WO2022256554A1 (en) | 2022-12-08 |
| AU2022287013A1 (en) | 2023-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3220850A1 (en) | Fluorinated tryptamine compounds, analogues thereof, and methods using same | |
| EP1300398B1 (en) | Propane-1,3-dione derivatives | |
| BR112016017808B1 (pt) | Composto ou sal farmaceuticamente aceitável, uso de um composto e composição para a inibição de um efeito betaamilóide numa célula neuronal | |
| JPH08109169A (ja) | 非ペプチドタキキニン受容体拮抗物質 | |
| KR20080094962A (ko) | 아미드 유도체 또는 그의 염 | |
| CA3046212A1 (en) | Heterocyclic inhibitors of mct4 | |
| TW201018467A (en) | Novel compounds as calcium channel blockers | |
| KR20090114439A (ko) | 아실구아니딘 유도체 | |
| UA100192C2 (en) | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands | |
| EP1701940A1 (en) | 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri | |
| SK9442002A3 (en) | Substituted phenyl-piperazine derivatives, their preparation and use | |
| US20240254087A1 (en) | Selective, partial, and arrestin-biased 5-ht2a agonists with utility in various disorders | |
| US12319682B2 (en) | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | |
| CA2926754A1 (en) | Piperazine derivatives and the use thereof as medicament | |
| AU2010340745B2 (en) | Sulfone compounds as 5-HT6 receptor ligands | |
| JP2012102018A (ja) | アミド化合物 | |
| CA2725740C (en) | 3-substituted propanamine compounds | |
| JP7340542B2 (ja) | 1-イミダゾチアジアゾロ-2h-ピロール-5-オン誘導体 | |
| TW202525792A (zh) | 經取代之側氧異吲哚啉基哌啶-2,6-二酮化合物 | |
| EA004248B1 (ru) | Производные 4-, 5-, 6- и 7-замещенного индола и индолина, их получение и применение | |
| CN117957211A (zh) | 氟化色胺化合物、其类似物及其使用方法 | |
| CN117447385A (zh) | 氘代的3-氨甲基-4-苯基哌啶-4-醇类化合物的制备及其用途 | |
| JP2024532558A (ja) | チエノ縮合環化合物及びその調製方法と使用 | |
| EP1860100B1 (en) | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | |
| KR20080070822A (ko) | 유도가능 산화질소 신타제 이량체화 억제제의 염 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250507 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250507 |